ERBB2 and gastric cancer: Although a phase I trial demonstrated that pyrotinib at 400 mg had well‐tolerated toxicity and promising efficacy in patients with HER2‐positive metastatic BC,9 rare safety and efficacy data of pyrotinib in HER2‐positive GC was ever reported.